Hype and hope of hepatic arterial infusion for colorectal cancer  

作　　者：François Ghiringhelli 

机构地区：[1]Centre de Recherche INSERM LNC-UMR1231,Dijon,France [2]University of Burgundy Franche-Comté,Dijon,France [3]Department of Medical Oncology,Centre Georges-François Leclerc,Dijon,France [4]Cancer Biology Transfer Platform,Centre Georges-François Leclerc,Dijon,France [5]Genetic and Immunology Medical Institute,Dijon,France

出　　处：《Hepatobiliary Surgery and Nutrition》2021年第2期235-237,共3页肝胆外科与营养（英文）

摘　　要：Contrary to most solid metastatic cancers,metastatic colorectal cancer could be cured by surgical removal of the metastasis in the context of lung or liver metastases.Large retrospective studies performed 20 years ago showed that surgery alone led to cure of the patient in about 35%of cases(1).To improve patient survival and to increase the cure rate,perioperative intravenous chemotherapy was proposed.In a large EORTC trial among highly selected patients,perioperative FOLFOX regimen improved relapse-free survival with an absolute difference in 3-year PFS of 8.1%(28.1%in the surgery-only group vs.36.2%in the perioperative chemotherapy group)and there was a non-significant increase in overall survival(5-year overall survival was 51.2%in the perioperative chemotherapy group vs.47.8%in the surgery-only group)(2).Despite this somewhat disappointing result,perioperative FOLFOX regimen became the standard of care for the management of resectable colorectal liver metastasis.

关 键 词：COLORECTAL CHEMOTHERAPY METASTASIS 

分 类 号：R73[医药卫生—肿瘤]